Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 4/2013

01.05.2013 | Hot Topics

Disease modification in systemic sclerosis

Do integrated approaches offer new challenges?

verfasst von: M. Cutolo, MD

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Excerpt

Despite intense efforts and significant advances in the management of organ-specific involvement and symptoms, systemic sclerosis (SSc) remains the autoimmune rheumatic disease with the highest progression and related mortality. The major perceived reason is the unavailability of successful disease-modifying (DM) therapeutic modalities [1]. …
Literatur
1.
Zurück zum Zitat Derk CT (2011) Disease-modifying drugs for systemic sclerosis: why have we not found them yet? Expert Rev Clin Immunol 7:399–401PubMedCrossRef Derk CT (2011) Disease-modifying drugs for systemic sclerosis: why have we not found them yet? Expert Rev Clin Immunol 7:399–401PubMedCrossRef
2.
Zurück zum Zitat Mendoza FA, Keyes-Elstein LL, Jimenez SA (2012) Systemic sclerosis disease modification clinical trials design: quo vadis? Arthritis Care Res (Hoboken) 64:945–954 Mendoza FA, Keyes-Elstein LL, Jimenez SA (2012) Systemic sclerosis disease modification clinical trials design: quo vadis? Arthritis Care Res (Hoboken) 64:945–954
3.
Zurück zum Zitat Geyer M, Müller-Ladner U (2011) The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 40:92–103PubMedCrossRef Geyer M, Müller-Ladner U (2011) The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 40:92–103PubMedCrossRef
4.
Zurück zum Zitat Hirschl M, Hirschl K, Lenz M et al (2006) Transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 54:1974–1981PubMedCrossRef Hirschl M, Hirschl K, Lenz M et al (2006) Transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 54:1974–1981PubMedCrossRef
5.
Zurück zum Zitat Cutolo M, Pizzorni C, Sulli A (2007) Identification of transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon by nailfold videocapillaroscopy. Arthritis Rheum 56:2102–2103PubMedCrossRef Cutolo M, Pizzorni C, Sulli A (2007) Identification of transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon by nailfold videocapillaroscopy. Arthritis Rheum 56:2102–2103PubMedCrossRef
6.
Zurück zum Zitat Herrick AL, Cutolo M (2010) Clinical implications from capillaroscopic analysis in patients with Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum 62:2595–2604PubMedCrossRef Herrick AL, Cutolo M (2010) Clinical implications from capillaroscopic analysis in patients with Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum 62:2595–2604PubMedCrossRef
7.
Zurück zum Zitat Jimenez SA, Derk CT (2004) Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140:37–50PubMedCrossRef Jimenez SA, Derk CT (2004) Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140:37–50PubMedCrossRef
8.
Zurück zum Zitat Dulmovits BM, Herman IM (2012) Microvascular remodeling and wound healing: a role for pericytes. Int J Biochem Cell Biol 44:1800–1812PubMedCrossRef Dulmovits BM, Herman IM (2012) Microvascular remodeling and wound healing: a role for pericytes. Int J Biochem Cell Biol 44:1800–1812PubMedCrossRef
9.
Zurück zum Zitat Bhattacharyya S, Wei J, Varga J (2011) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42–54PubMedCrossRef Bhattacharyya S, Wei J, Varga J (2011) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42–54PubMedCrossRef
10.
Zurück zum Zitat Distler JH, Jüngel A, Pileckyte M et al (2007) Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 561:4203–4215CrossRef Distler JH, Jüngel A, Pileckyte M et al (2007) Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 561:4203–4215CrossRef
11.
Zurück zum Zitat Müller-Ladner U, Distler O, Ibba-Manneschi L et al (2009) Mechanisms of vascular damage in systemic sclerosis. Autoimmunity 42:587–595PubMedCrossRef Müller-Ladner U, Distler O, Ibba-Manneschi L et al (2009) Mechanisms of vascular damage in systemic sclerosis. Autoimmunity 42:587–595PubMedCrossRef
12.
Zurück zum Zitat Manetti M, Guiducci S, Matucci-Cerinic M (2011) The origin of the myofibroblast in fibroproliferative vasculopathy: does the endothelial cell steer the pathophysiology of systemic sclerosis? Arthritis Rheum 63:2164–2167PubMedCrossRef Manetti M, Guiducci S, Matucci-Cerinic M (2011) The origin of the myofibroblast in fibroproliferative vasculopathy: does the endothelial cell steer the pathophysiology of systemic sclerosis? Arthritis Rheum 63:2164–2167PubMedCrossRef
13.
14.
Zurück zum Zitat Bhattacharyya S, Wei J, Varga J (2011) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42–54PubMedCrossRef Bhattacharyya S, Wei J, Varga J (2011) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42–54PubMedCrossRef
15.
Zurück zum Zitat Widyantoro B, Emoto N, Nakayama K et al (2010) Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 121:2407–2418PubMedCrossRef Widyantoro B, Emoto N, Nakayama K et al (2010) Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 121:2407–2418PubMedCrossRef
16.
Zurück zum Zitat Nataraj D, Ernst A, Kalluri R (2010) Idiopathic pulmonary fibrosis is associated with endothelial to mesenchymal transition. Am J Respir Cell Mol Biol 43:129–130PubMedCrossRef Nataraj D, Ernst A, Kalluri R (2010) Idiopathic pulmonary fibrosis is associated with endothelial to mesenchymal transition. Am J Respir Cell Mol Biol 43:129–130PubMedCrossRef
17.
Zurück zum Zitat Mouthon L, Mehrenberger M, Teixeira L et al (2011) Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 42:95–102PubMedCrossRef Mouthon L, Mehrenberger M, Teixeira L et al (2011) Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 42:95–102PubMedCrossRef
18.
Zurück zum Zitat Soldano S, Montagna P, Brizzolara R et al (2012) Transforming growth factor-β and endothelin-1 induce endothelial-to-mesenchymal transition in cultured human endothelial cells. Arthritis Rheum 64:abstract 1493 Soldano S, Montagna P, Brizzolara R et al (2012) Transforming growth factor-β and endothelin-1 induce endothelial-to-mesenchymal transition in cultured human endothelial cells. Arthritis Rheum 64:abstract 1493
19.
Zurück zum Zitat Li Z, Jimenez SA (2011) Protein kinase Cdelta and c-Abl kinase are required for transforming growth factor beta induction of endothelial-to-mesenchymal transition in vitro. Arthritis Rheum 63:2473–2483PubMedCrossRef Li Z, Jimenez SA (2011) Protein kinase Cdelta and c-Abl kinase are required for transforming growth factor beta induction of endothelial-to-mesenchymal transition in vitro. Arthritis Rheum 63:2473–2483PubMedCrossRef
20.
Zurück zum Zitat Cutolo M, Sulli A, Secchi ME, Pizzorni C (2006) Capillaroscopy and rheumatic diseases: state of the art. Z Rheumatol 65:290–296PubMedCrossRef Cutolo M, Sulli A, Secchi ME, Pizzorni C (2006) Capillaroscopy and rheumatic diseases: state of the art. Z Rheumatol 65:290–296PubMedCrossRef
21.
Zurück zum Zitat Smith V, Decuman S, Sulli A et al (2012) Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? A pilot study. Ann Rheum Dis 71:1636–1639PubMedCrossRef Smith V, Decuman S, Sulli A et al (2012) Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? A pilot study. Ann Rheum Dis 71:1636–1639PubMedCrossRef
22.
Zurück zum Zitat Cutolo M, Sulli A, Pizzorni C, Accardo S (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27:155–160PubMed Cutolo M, Sulli A, Pizzorni C, Accardo S (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27:155–160PubMed
23.
Zurück zum Zitat Avouac J, Fransen J, Walker UA et al (2011) EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 70:476–481PubMedCrossRef Avouac J, Fransen J, Walker UA et al (2011) EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 70:476–481PubMedCrossRef
24.
Zurück zum Zitat LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed
25.
Zurück zum Zitat Johnson SR, Fransen J, Khanna D et al (2012) Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 64:358–367CrossRef Johnson SR, Fransen J, Khanna D et al (2012) Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 64:358–367CrossRef
26.
Zurück zum Zitat Smith V, Decuman S, Sulli A et al (2012) Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? a pilot study. Ann Rheum Dis 71:1636–1639PubMedCrossRef Smith V, Decuman S, Sulli A et al (2012) Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? a pilot study. Ann Rheum Dis 71:1636–1639PubMedCrossRef
27.
Zurück zum Zitat Smith V, De Keyser F, Pizzorni C et al (2011) Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis 70:180–183PubMedCrossRef Smith V, De Keyser F, Pizzorni C et al (2011) Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis 70:180–183PubMedCrossRef
28.
Zurück zum Zitat Sulli A, Pizzorni C, Smith V et al (2012) Timing of transition between capillaroscopic patterns in systemic sclerosis. Arthritis Rheum 64:821–825PubMedCrossRef Sulli A, Pizzorni C, Smith V et al (2012) Timing of transition between capillaroscopic patterns in systemic sclerosis. Arthritis Rheum 64:821–825PubMedCrossRef
29.
Zurück zum Zitat Tugwell P, Pincus T, Yocum D et al (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 333:137–141PubMedCrossRef Tugwell P, Pincus T, Yocum D et al (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 333:137–141PubMedCrossRef
30.
Zurück zum Zitat Kuhn A, Haust M, Ruland V et al (2010) Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 49(7):1336–1345 Kuhn A, Haust M, Ruland V et al (2010) Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 49(7):1336–1345
31.
Zurück zum Zitat Piera-Velazquez S, Jimenez SA (2012) Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis Tissue Repair 5(Suppl 1):S7PubMedCrossRef Piera-Velazquez S, Jimenez SA (2012) Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis Tissue Repair 5(Suppl 1):S7PubMedCrossRef
32.
Zurück zum Zitat Guiducci S, Bellando Randone S, Bruni C et al (2012) Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 31:1723–1725PubMedCrossRef Guiducci S, Bellando Randone S, Bruni C et al (2012) Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 31:1723–1725PubMedCrossRef
33.
Zurück zum Zitat Cutolo M, Zampogna G, Vremis L et al (2013) Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol 40:40–45PubMedCrossRef Cutolo M, Zampogna G, Vremis L et al (2013) Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol 40:40–45PubMedCrossRef
Metadaten
Titel
Disease modification in systemic sclerosis
Do integrated approaches offer new challenges?
verfasst von
M. Cutolo, MD
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 4/2013
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-013-1157-2

Weitere Artikel der Ausgabe 4/2013

Zeitschrift für Rheumatologie 4/2013 Zur Ausgabe

Neues aus der Forschung

B‐Zellen

Mitteilungen der DGRh

Mitteilungen

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.